Rashmi Chugh, MD

Professor of Internal Medicine
University of Michigan

Dr. Rashmi Chugh is a medical oncologist at Rogel Comprehensive Cancer Center, University of Michigan in Ann Arbor, MI. She completed her undergraduate training at Northwestern University followed by medical school at Washington University in Saint Louis. She proceeded to residency, oncology fellowship and currently is faculty at University of Michigan where she has a clinical focus on the care of soft tissue and bone sarcoma patients.

Dr. Chugh currently serves as co-lead of the Connective Oncology Clinical Research Team at Rogel Comprehensive Cancer Center, co-medical director of the Michigan Adolescent and Young Adult Oncology program and Associate Division Chief of Clinical Services. She is a member of the Desmoid Tumor Research Foundation, National Leiomyosarcoma Foundation and Clear Cell Sarcoma Foundation Medical Advisory Boards. Her research interests include early phase studies in soft tissue, bone sarcoma and desmoid tumors and genomics of connective tissue malignancies.

Poster(s):

• (P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS

• (P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA

• (P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY

• (P 266) EFFICACY OF LIPOSOMAL DOXORUBICIN IN PATIENTS WITH INTRA- AND EXTRA-ABDOMINAL DESMOID FIBROMATOSIS

• (P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)

• (P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT